In conclusion, WEAF and its key active compounds, glycitein and isorhapontigenin, effectively ameliorate obesity-induced NAFLD via the NF-κB/PPAR-γ signaling pathway by targeting TLR2, supporting their potential as therapeutic target and agents for NAFLD. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.